RenovoRx’s TAMP Platform Revolutionizes Cancer Therapy


RenovoRx (Nasdaq: RNXT), a clinical-stage biopharmaceutical company, is advancing novel precision oncology therapies through its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform. This platform represents a paradigm shift in cancer treatment, specifically targeting solid tumors with localized chemotherapy delivery, thereby minimizing systemic side effects commonly associated with traditional intravenous methods.

Recently, RenovoRx announced promising pre-clinical study results validating the efficacy and precise drug delivery mechanism of its TAMP platform. This development underscores its potential to significantly enhance therapeutic outcomes for patients with difficult-to-treat solid tumors, including pancreatic cancer, which remains one of the deadliest forms of cancer.

The 10 deadliest cancers

  • Pancreatic cancer.
  • Liver cancer and intrahepatic bile duct cancer.
  • Esophageal cancer.
  • Lung cancer and bronchus cancer.
  • Acute myeloid leukemia.
  • Brain cancer and other nervous system cancer.
  • Stomach cancer.
  • Ovarian cancer.

Dr. Farsad, a key figure in RenovoRx’s clinical initiatives, highlighted the platform’s ability to elevate local therapeutic concentrations within tumors independently of conventional catheter-directed therapies. Currently undergoing Phase III clinical trials, TAMP holds promise to address critical unmet needs in localized therapeutic drug delivery.

RenovoRx’s commitment to innovation is further underscored by the FDA Orphan Drug Designation granted to RenovoGem™ for pancreatic and bile duct cancers. This designation provides significant market exclusivity upon New Drug Application (NDA) approval, emphasizing the potential impact of RenovoRx’s therapies in addressing rare and life-threatening diseases.

Additionally, RenovoRx is advancing TIGer-Pac, a study aimed at optimizing treatment strategies for locally advanced pancreatic cancer (LAPC) patients following stereotactic body radiation therapy (SBRT). This study compares the efficacy of TAMP-delivered gemcitabine versus conventional intravenous administration in improving patient outcomes.

In conclusion,

RenovoRx’s groundbreaking approach to cancer therapy not only holds promise for enhancing survival rates and reducing toxicity but also exemplifies its dedication to addressing critical medical challenges. As the company continues to advance its pipeline and explore strategic partnerships, its impact on improving the lives of cancer patients worldwide becomes increasingly apparent.

No comment

Leave a Reply

Your email address will not be published. Required fields are marked *